Welcome to the 10th meeting of the Medicon Valley Alliance Oncology Network on 8th of December.
Medicon Valley Alliance, together with Lund University and the University of Copenhagen, has the pleasure to invite you to the 10th MVA Oncology Network meeting.
This event will focus on transitioning towards personalised medicine for cancer patients by combining genomic, proteomic and clinical information.
To date, the disease presentation in cancer patients constitutes great challenges to the healthcare system and tumour heterogeneity often leads to drug resistance and relapse of the disease. A combined approach of genomics, proteomics and clinical data will allow today’s healthcare to enter an era of personalised medicine.
Please join us and learn about the successful research in the Öresund region and a discussion about further collaboration between academia, healthcare and industry within the field.
Due to the current Covid-19 situation in Denmark and Sweden this meeting is delivered in a shorter webinar format instead of a regular networking meeting.
|Date:||8th of December, 2020|
|Venue:||Online – Registered participants will receive the link to the meeting a few days before the event|
|Moderator: Johan Malm, Professor Clinical Chemistry, Lund University|
|14.50-15.00||Online platform open for connecting participants|
|15.00-15.05||Welcome by Petter Hartman, CEO, Medicon Valley Alliance|
Introduction to today’s program, Johan Malm, Professor Clinical Chemistry, Lund University
|15.05-15.10||The value of IP in personalised medicine|
Jens Viktor Nørgaard, Partner, Head of Biotechnology & Plant Sciences, European Patent Attorney, Høiberg
|15.10-15.20||European Cancer Moonshot Center Lund|
György Marko Varga, Professor Clinical protein Science and Imaging, Lund University
|15.20-15.30||Whole-genome sequencing, mutational signatures and interventions in cancer therapy|
Eva Hoffmann, Professor Molecular Genetics, University of Copenhagen
|15.30-15.40||Challenges in Cancer Pathology|
Martin Johansson, Professor, Clinical Pathology, Lund University
|15.40-15.50||Tissue diagnostics of the future|
Krzysztof Krawczyk, Project Manager, Lumito AB
|15.50-16.00||Scandion Oncology – Clinical Phase II biotechnology company targeting cancer drug resistance|
Jan Stenvang, Chief Technology Officer, Scandion Oncology A/S
|16.00-16.10||Public- private partnerships: a strong way forward to maximize impact|
Erik Steinfelder, Biobanking Market Development Director, Thermo Fisher Scientific
|16.10-16.25||Panel discussion: Potential areas for collaboration in Medicon Valley|
|16.25-16.30||Final remarks and conclusions|
Johan Malm, Professor Clinical Chemistry, Lund University, György Marko Varga, Professor Clinical protein Science and Imaging, Lund University
Deadline for registration is 4th of December, 2020.
For more information please contact Sofia Norås email@example.com
MVA Oncology Network is a professional and social network for professors, PIs and corporate level executives from the regional oncology eco-system. The network focuses on best practice, experience and current challenges for public-private collaboration and the commercialization of oncology related R&D in the Medicon Valley region.
Joining the network is free of charge and is limited to Medicon Valley Alliance members only. However, non-member organizations and companies are welcome to attend one network event to evaluate if joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the oncology network.